Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

(2021) Pratishtha Chatterjee et al.   Translational Psychiatry

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation

(2021) Samantha Prins et al.   Alzheimers Research & Therapy

Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective

(2021) Billy Dunn et al.   JAMA Internal Medicine

Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies

(2020) Henrik Zetterberg et al.   MOLECULAR PSYCHIATRY

The role of microglia in the development of neurodegeneration

(2020) Aigul R. Saitgareeva et al.   NEUROLOGICAL SCIENCES

Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients

(2020) Christiana Bjorkli et al.   Frontiers in Aging Neuroscience

Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers

(2020) Andrea Vergallo et al.   NEUROBIOLOGY OF AGING

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

(2019) Patrick Oeckl et al.   JOURNAL OF ALZHEIMERS DISEASE

Inflammatory biomarkers in Alzheimer's disease plasma

(2019) Angharad R. Morgan et al.   Alzheimers & Dementia

Plasma YKL-40 in the spectrum of neurodegenerative dementia

(2019) Anna Villar-Piqué et al.   Journal of Neuroinflammation

Serum glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 for diagnosis of sepsis-associated encephalopathy and outcome prognostication

(2019) Long Wu et al.   JOURNAL OF CRITICAL CARE

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Biomarkers for Alzheimer's disease: current status and prospects for the future

(2018) K. Blennow et al.   JOURNAL OF INTERNAL MEDICINE

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

(2018) Heidi Högel et al.   Multiple Sclerosis Journal

Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases

(2017) Filippo Baldacci et al.   Expert Review of Proteomics

Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease

(2017) Sarah Jesse et al.   JOURNAL OF ALZHEIMERS DISEASE

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective

(2015) Piotr Lewczuk et al.   Advances in Medical Sciences

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

(2015) Konstantin Hellwig et al.   Alzheimers Research & Therapy

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

(2009) C. E. Teunissen et al.   NEUROLOGY